-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/erythropoiesis-stimulating-agents-utilization_research.pdf
February 01, 2011 - agents among Medicare beneficiaries with kidney disease
Erythropoietins Data Points #4
The findings described … The work described herein was commissioned for presentation
at the March 24, 2010, Medicare Evidence … These groups are more
thoroughly described in the subsequent
Definitions and Methodology section. … 4
Relating Timing of Practice and
Policy Events to Potential Impact on
ESA Use
As previously described … DEFINITIONS AND METHODOLOGY
Eligible Population
Unless otherwise specified, the ESA utilization described
-
psnet.ahrq.gov/node/865813/psn-pdf
May 08, 2024 - Participants reported
increased convenience (e.g., patients not having to miss work), but also described
-
psnet.ahrq.gov/node/866316/psn-pdf
July 17, 2024 - In this
study, recently hospitalized patients described the various ways they tried to improve their
-
psnet.ahrq.gov/node/36889/psn-pdf
May 28, 2024 - Research and Quality
https://psnet.ahrq.gov/issue/surveys-patient-safety-culture
Safety culture has been described
-
psnet.ahrq.gov/node/867640/psn-pdf
February 26, 2025 - Patients and
providers described limitations with describing and examining relevant symptoms, as patients
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/cancer-ovarian-contraceptives_research-protocol.pdf
March 13, 2012 - This process is described further in section IV F. … The safety outcomes will be
framed to help identify adverse events as described in KQ 5. … Data necessary for
assessing quality and applicability, as described in the General Methods Guide,20 … These
outcomes were de-
prioritized following the
ranking process
described in Sections II
and IV … These outcomes
were de-prioritized
following the ranking
process described in
Sections II and IV
-
psnet.ahrq.gov/node/854636/psn-pdf
October 18, 2023 - customization and
individualization (e.g., simplifying medication regimens for certain patients) and described
-
psnet.ahrq.gov/node/849330/psn-pdf
May 24, 2023 - Prescribers described the usefulness of CDS but also noted alert fatigue.
-
psnet.ahrq.gov/node/838019/psn-pdf
September 07, 2022 - This study characterizes safety measures described in incident reports from German
outpatient care settings
-
psnet.ahrq.gov/node/851055/psn-pdf
June 28, 2023 - In this study, surgical trainees described factors influencing their decisions
not to disclose errors
-
psnet.ahrq.gov/node/50887/psn-pdf
February 12, 2020 - Successful
elements are described, and the authors conclude that an openness to continuous improvement
-
psnet.ahrq.gov/node/851648/psn-pdf
July 26, 2023 - In this study,
25 hospitalized Black patients with serious illness described their experiences with
-
psnet.ahrq.gov/node/841762/psn-pdf
December 21, 2022 - In this study, nurse anesthetists and intensive care
nurses described strategies to ensure safe transport
-
psnet.ahrq.gov/node/47776/psn-pdf
August 20, 2021 - A WebM&M commentary described the challenges and benefits associated with
robotic surgery.
-
psnet.ahrq.gov/node/73465/psn-pdf
July 07, 2021 - Most errors described usability issues which should be considered and addressed to improve
medication
-
psnet.ahrq.gov/node/841474/psn-pdf
January 01, 2023 - The challenges and strategies described in the
publication can be used by health systems to accelerate
-
psnet.ahrq.gov/node/48110/psn-pdf
August 14, 2019 - A recent WebM&M commentary described how leaders can encourage
and reward speaking up.
-
psnet.ahrq.gov/node/39057/psn-pdf
December 30, 2014 - a missing dose clarification request, a related near miss, and
medication name confusion are also described
-
psnet.ahrq.gov/node/35288/psn-pdf
September 12, 2016 - A number of dramatic cases are described (including several that were fatal), as
are some of the challenges
-
psnet.ahrq.gov/web-mm/acute-care-admission-behavioral-health-patient
July 19, 2023 - In addition, the GI consult described how the patient requested a reduction in the haloperidol dose because … Adverse motor effects associated with this antagonism (e.g., Parkinsonism and dystonia) were described … At least one case report has described this pattern with olanzapine.( 11 ) Withdrawal dyskinesias, presumably … related to dopaminergic sensitivity, are also described.( 12 ) Additional discontinuation symptoms,